Biotech IV Monitor

AMLX — Amylyx Pharmaceuticals Inc.

$2.0B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Amylyx Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$2.0B
Cash & investments$768M~17 quarters at last loss rate
Recent 8-K filings1latest 2026-11-05

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 Avexitide
Post Bariatric Hypoglycemia · NCT06747468
July 2026
Primary data collected

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 3 Avexitide (Exendin 9-39)
Post-Bariatric Hypoglycemia (PBH)
January 30, 2019
Enrollment Conclusion

Cash position

Amylyx Pharmaceuticals Inc. reported $768M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $45M; at that rate the cash would last about 17 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Discussion

No messages yet. If you follow AMLX, you can start the conversation.
Track AMLX in real time
See live implied volatility for AMLX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on AMLX
Contact — questions or corrections about AMLX: dukeupt@gmail.com